



## Clinical trial results: Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma Summary

EudraCT number	2010-022180-35
Trial protocol	DE
Global end of trial date	22 April 2015

### Results information

Result version number	v1 (current)
This version publication date	19 March 2020
First version publication date	19 March 2020

### Trial information

#### Trial identification

Sponsor protocol code	Uni-Koeln-1432
-----------------------	----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01187303
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	University of Cologne
Sponsor organisation address	Albertus Magnus-Platz, Köln, Germany, 50923
Public contact	Trial Coordination Center of the German Hodgkin Study Group (GHSG), German Hodgkin Study Group (GHSG), 0049 22147888200, ghsg@uk-koeln.de
Scientific contact	Trial Coordination Center of the German Hodgkin Study Group (GHSG), German Hodgkin Study Group (GHSG), 0049 22147888200, ghsg@uk-koeln.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 June 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 April 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary aim of the trial was to implement the fully human monoclonal anti-CD20 antibody ofatumumab into the treatment of patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and to determine whether treatment with ofatumumab was likely to meet a basic level of efficacy in this setting.

Protection of trial subjects:

Written informed consent prior to study entry; Weekly blood test during therapy; Premedication with acetaminophen , antihistamine and glucocorticoid before each ofatumumab infusion; Reduced infusion rate in case of AEs

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 July 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	12 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 28
Worldwide total number of subjects	28
EEA total number of subjects	28

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	26

From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Between 05 July 2011 and 26 February 2014, 28 patients were recruited in one German trial site.

### Pre-assignment

Screening details:

Main entry criteria were relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), age 18-75 years, no anti-CD20 antibody treatment in the six months prior to enrollment. Main exclusion criteria were composite lymphoma, concurrent disease which precludes protocol treatment, pregnancy, lactation.

### Period 1

Period 1 title	Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Intervention
Arm description:	
Intervention Group	
Arm type	Experimental
Investigational medicinal product name	Ofatumumab
Investigational medicinal product code	L01XC10
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The investigational medical product, ofatumumab, is a liquid concentrate for solution presented in glass vials. Ofatumumab will be infused intravenously at 300 mg in the first week, followed by seven weekly infusions at 1000 mg. In case of delay > 2 weeks the patient will be excluded from the trial. The ofatumumab infusions will be prepared by the pharmacy of the University Hospital Cologne in 1000 mL NaCl sterile, pyrogen free 0.9% NaCl to yield a 0.3 mg/mL and 1 mg/mL ofatumumab concentration for the first and subsequent infusions, respectively.

<b>Number of subjects in period 1</b>	Intervention
Started	28
Completed	28

## Baseline characteristics

### Reporting groups

Reporting group title	Trial
Reporting group description: -	

Reporting group values	Trial	Total	
Number of subjects	28	28	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	26	26	
From 65-84 years	2	2	
85 years and over	0	0	
Age continuous			
Units: years			
median	44.5		
full range (min-max)	22 to 68	-	
Gender categorical			
Units: Subjects			
Female	10	10	
Male	18	18	

### Subject analysis sets

Subject analysis set title	Primary endpoint analysis set
Subject analysis set type	Per protocol

Subject analysis set description:

Patients who receive less than 4 infusions for reasons other than progressive disease or who discontinue treatment for other reasons than adverse events or who drop out before completion of the final restaging cannot be evaluated for the primary efficacy endpoint and will be replaced.

Reporting group values	Primary endpoint analysis set		
Number of subjects	28		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		

Adolescents (12-17 years)	0		
Adults (18-64 years)	26		
From 65-84 years	2		
85 years and over	0		
Age continuous			
Units: years			
median	44.5		
full range (min-max)	22 to 68		
Gender categorical			
Units: Subjects			
Female	10		
Male	18		

---

## End points

### End points reporting groups

Reporting group title	Intervention
Reporting group description:	
Intervention Group	
Subject analysis set title	Primary endpoint analysis set
Subject analysis set type	Per protocol
Subject analysis set description:	
Patients who receive less than 4 infusions for reasons other than progressive disease or who discontinue treatment for other reasons than adverse events or who drop out before completion of the final restaging cannot be evaluated for the primary efficacy endpoint and will be replaced.	

### Primary: Objective Response Rate

End point title	Objective Response Rate <sup>[1]</sup>
End point description:	
The objective response rate (ORR) is the proportion of patients showing an overall tumor response (CR, CRr, PR) at the CT-based restaging 3 months after completion of study treatment. The one-sided 95% confidence interval for the ORR ranged from 84.2% to 100% and thus excluded the predefined efficacy benchmark of 70%.	
End point type	Primary
End point timeframe:	
3 months after completion of study treatment	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single-arm study with no comparison. It is not possible to enter a single-arm analysis in the system. The primary statistical analysis was as follows. The null hypothesis H0 "ORR < 70%" was tested versus a one-sided alternative via a one-sided exact binomial 95% confidence interval. The respective confidence interval ranged from 84.2% to 100% and thus excluded the predefined efficacy benchmark.

End point values	Intervention	Primary endpoint analysis set		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	28	28		
Units: totals				
Objective response	27	27		
No objective response	1	1		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

First application of study treatment until 28 days after last dose of study medication. After that, all AEs that are judged at least as possibly related to the treatment by the investigator, had to be documented until end of study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	10.1

### Reporting groups

Reporting group title	Safety set
-----------------------	------------

Reporting group description:

The safety set consists of all patients of the FAS who had at least one valid post-baseline safety assessment (as documented on the therapy CRF or on the AE CRF).

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only AEs of CTCAE grade  $\geq 3$  were to be recorded in this study. No non-serious AE of CTCAE grade  $\geq 3$  has been reported.

Serious adverse events	Safety set		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 28 (3.57%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Infections and infestations			
Myocarditis post infection			
subjects affected / exposed	1 / 28 (3.57%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Safety set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 28 (0.00%)		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/26585412>